Zoetis (ZTS) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Zoetis Inc. dominates the veterinary sector, leveraging patents for flexible pricing power. The company's historical EV/EBITDA trend confirms this strength, where 10.22 represents the current level of the metric. Growth is based on the strategic acquisition of diagnostic startups and the implementation of sustainable production standards through a transition to biodegradable packaging.

ZTS (Zoetis Inc) Business Value to Operating Income Before Depreciation history from 11/23/2025 to 11/12/2026

zoetis.com - analytical breakdowns and key metrics (ZTS)

- current price and projected stock value:

Stock Price Zoetis Corp|ZTS - Analyst Median Target

- market capitalization details:

Market Value Zoetis Corporation|ZTS - Company Buyout Price

- book value of equity indicators:

Accounting Value per Share Zoetis|ZTS - Accounting Value of Company|Market Capitalization to Book Value Ratio zoetis.com|ZTS - Company Total Asset Base

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

ZTS - Profit After Payment of Taxes|Expected Profit Zoetis Inc.|ZTS - Business Payback Period|Future Price to Earnings Zoetis Inc.|ZTS - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Zoetis Corporation|ZTS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Zoetis|ZTS - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months zoetis.com|ZTS - Expected net earnings per share growth this year|Expected earnings per share growth for next year Zoetis Inc.

Analysis of all company metrics:Zoetis Corp (ZTS)

Investors are seeking fundamental stability by analyzing business value relative to operating profit. This indicator compares the enterprise value (EV), including debt, with EBITDA, excluding the impact of taxes and depreciation. For Zoetis Inc. (ZTS), with its scalable R&D model and low drug production costs, this metric confirms the efficiency of its cash generation. The dynamic EV/EBITDA value of Zoetis Inc. (ZTS) allows for the determination of a fair premium for its leadership in veterinary pharmaceuticals.

Analysis of competing companies

EV/EBITDA Multiple CHWY (Chewy Corp)|Total Company Value to Operating Income Before Depreciation Ratio Freshpet Brand (FRPT)|CENT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio trupanion.com TRUP|WOOF (Petco) - Enterprise Value to EBITDA Ratio|Dogness (International) Corporation - Business Value to Operating Income Before Depreciation|BARK (BARK, Inc.) - EV/EBITDA Multiple|1-800-PetMeds (PETS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TDH Holdings, Inc. (PETZ)|boqii.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple IVP (Inspire Veterinary Partners, Inc.)|BTTR - Enterprise Value to EBITDA Ratio|PET: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio PetIQ Corporation PETQ|ZOM (zomedica.com) - Enterprise Value to EBITDA Ratio